Glaucoma Patents (Class 514/913)
  • Patent number: 5811443
    Abstract: Combinations of at least one clonidine derivative and at least one prostaglandin are used to treat glaucoma and ocular hypertension without some of the side effects typically associated with topical administration of prostaglandins.
    Type: Grant
    Filed: February 21, 1997
    Date of Patent: September 22, 1998
    Assignee: Alcon Laboratories, Inc.
    Inventors: Louis DeSantis, Jr., Verney L. Sallee
  • Patent number: 5798369
    Abstract: The present invention provides a novel use of a compound of formula I ##STR1## or a pharmaceutically and/or physiologically acceptable salt or solvate thereof for the manufacture of a pharmaceutical composition useful for lowering intraocular pressure.
    Type: Grant
    Filed: July 7, 1997
    Date of Patent: August 25, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Niels Korsgaard, John Romer
  • Patent number: 5798380
    Abstract: Methods for the treatment of glaucoma are described. The compounds described cause a perturbation of cell adhesions in the trabecular meshwork, mainly via disruption of the associated cytoskeletal structures or the modulation of their interactions with the underlying membrane. Perturbation of these adhesions reduces the resistance of the trabecular meshwork to fluid flow and thereby reduces intraocular pressure.
    Type: Grant
    Filed: February 21, 1996
    Date of Patent: August 25, 1998
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Paul L. Kaufman, Benjamin Geiger
  • Patent number: 5783606
    Abstract: Methods and kits for treatment of glaucoma are disclosed. In general, the methods of the invention include administering a therapeutically effective amount of a deprenyl compound to a subject such that the subject is treated for glaucoma.
    Type: Grant
    Filed: February 9, 1996
    Date of Patent: July 21, 1998
    Assignee: The University of Toronto Innovations Foundation
    Inventor: William G. Tatton
  • Patent number: 5776916
    Abstract: A medicament for reduction of intraocular pressure comprises both carbachol and a locally applicable betablocker.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 7, 1998
    Inventor: Eugen Gramer
  • Patent number: 5767154
    Abstract: The invention relates to the use of derivatives of F-type prostaglandins as ocular hypotensives. The PGF derivatives used in accordance with the invention are encompassed by the following structure formula I: ##STR1## wherein wavy line attachments indicate either the alpha (a) or beta (b) configuration; hatched lines indicate a configuration, solid triangles are used to indicate b configuration, dashed bonds represent a double bond, or a single bond; n is 0, or an integer of from 1 to 3; X is NH.sub.2 or OR; R is hydrogen, R.sub.4 or a --(CO)R.sub.4 group; R.sub.1, R.sub.2, and R.sub.3 independently are hydroxyl, or --O(CO)R.sub.5 groups, wherein R.sub.4 and R.sub.5 independently stand for saturated or unsaturated acyclic hydrocarbon having from 1 to 20 carbon atoms, or --(CH.sub.2).sub.m R.sub.6 where m is 0-10 and R.sub.6 is an aliphatic, aromatic or heteroaromatic ring, R.sub.7 and R.sub.8 together are .dbd.
    Type: Grant
    Filed: March 24, 1997
    Date of Patent: June 16, 1998
    Assignee: Allergan
    Inventors: David A. Woodward, Ming F. Chan
  • Patent number: 5756549
    Abstract: Compounds characterized generally as alkylaminoalkyl-terminated sulfide/sulfonyl-containing cycloalkylalkyl alanine amino-diol derivatives are useful as renin inhibitors for the treatment of hypertension. Compounds of particular interest are those of Formula II: ##STR1## wherein m is is two or three; wherein x is zero or two; wherein R.sup.2 is selected from hydrido, methyl, ethyl and phenyl; wherein R.sup.3 is selected from hydrido, cyclohexylmethyl, benzyl, fluorobenzyl, chlorobenzyl, fluoronaphthylmethyl and chloronaphthylmethyl; wherein R.sup.5 is selected from cycloalkylalkyl groups containing from three to about twelve carbon atoms; wherein R.sup.7 is cyclohexylmethyl; wherein R.sup.8 is selected from n-propyl, isobutyl, cyclopropyl;, cyclopropylmethyl, allyl and vinyl; and wherein each of R.sup.9 and R.sup.10 is a group independently selected from methyl, ethyl and isopropyl; or a pharmaceutically-acceptable salt thereof.
    Type: Grant
    Filed: January 29, 1996
    Date of Patent: May 26, 1998
    Assignee: G. D. Searle & Co.
    Inventors: Barbara B. Chen, Gunnar J. Hanson, John S. Baran
  • Patent number: 5733938
    Abstract: Disclosed are pharmaceutical compositions comprising dipivefrin and levobunolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.
    Type: Grant
    Filed: September 9, 1994
    Date of Patent: March 31, 1998
    Assignee: Allergan
    Inventors: Orest Olejnik, Gary D. Novack
  • Patent number: 5731005
    Abstract: The present invention provides a sustained-release delivery composition for ophthalmic drugs comprising cross-linked hydrogel microspheres having a binding affinity for the drug.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: March 24, 1998
    Assignee: Vitaphore Corporation
    Inventors: Thomas B. Ottoboni, Lisa B. Jungherr, Ronald K. Yamamoto
  • Patent number: 5721273
    Abstract: 9-Halo-13,14-dihydroprostaglandins are useful in the treatment of glaucoma and ocular hypertension. Also disclosed are ophthalmic, pharmaceutical compositions comprising such prostaglandins.
    Type: Grant
    Filed: December 15, 1993
    Date of Patent: February 24, 1998
    Assignee: Alcon Laboratories, Inc.
    Inventors: Verney L. Sallee, Louis DeSantis, Jr., Paul W. Zinke, John E. Bishop
  • Patent number: 5716952
    Abstract: Pharmaceutical compositions and a method are disclosed for treating glaucoma and/or ocular hypertension in the mammalian eye by administering to the mammalian eye the pharmaceutical composition of the invention which contains as the active ingredient one or more muscarinic antagonist compounds. Examples of muscarinic antagonists utilized in the pharmaceutical composition and method of treatment are: 10H-thieno(3,4-b)(1,5)benzodiazepin-10-one 4,9-dihydro-3-methyl-4-((4-methyl-1-piperazinyl)acetyl) (telenzepine); 5,11-dihydro-11?4'-methyl-1'-piperazinyl)-acetyl!-6H-pyrido?2,3-b!?1,4!ben zodiazepin-6-one (pirenzepine); racemic 11-??2-(Diethylamino)methyl!-1-piperidinyl!-acetyl!-5,11-dihydro-6H-pyrido ?2,3-b!?1,4!benzodiazepin-6-one (AF-DX 116); dextrorotatory 11-??2-(Diethylamino)methyl!-1-piperidinyl!-acetyl!-5,11-dihydro-6H-pyrido ?2,3-b!?1,4! benzodiazepin-6-one (AF-DX 250); an ophthalmically acceptable salt of 4-diphenylacetoxy-1,1-dimethyl piperidine (4-DAMP); .alpha.-cyclohexyl, -.alpha.
    Type: Grant
    Filed: March 18, 1992
    Date of Patent: February 10, 1998
    Assignee: Allergan
    Inventors: Elizabeth WoldeMussie, Guadalupe Ruiz
  • Patent number: 5716632
    Abstract: In a preferred embodiment, drugs having pharmacological properties which are useful in the medicinal therapy of fibrotic disease for the reparation and prevention of fibrotic lesional tissues, such drugs including as active ingredient(s) one or more N-substituted 2-(1H) pyridone(s) and/or N-substituted 3-(1H) pyridones. The composition of this invention is novel as an anti-fibrotic drug, namely, as an agent for treating fibrosis. Any existing compounds have not been shown to be effective for the reparation and prevention of fibrotic lesions.
    Type: Grant
    Filed: May 9, 1996
    Date of Patent: February 10, 1998
    Inventor: Solomon B. Margolin
  • Patent number: 5716966
    Abstract: The subject invention involves methods of treating nasal congestion comprising administration, to a human or lower animal in need of such treatment of a safe and effective amount of a compound having the following structure: ##STR1## wherein: (a) R is unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl; and(b) R' is selected from hydrogen; unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl; unsubstituted C.sub.1 -C.sub.3 alkylthio or alkoxy; hydroxy; thiol; cyano; and halo.The subject invention also involves the use of such compounds for preventing or treating other respiratory, ocular and/or gastrointestinal disorders. The subject invention also involves novel compounds having the above structure wherein R' is hydrogen or fluoro or cyano.
    Type: Grant
    Filed: June 29, 1995
    Date of Patent: February 10, 1998
    Assignee: The Procter & Gamble Company
    Inventors: Thomas Lee Cupps, Sophie Eva Bogdan
  • Patent number: 5710165
    Abstract: Polyamine antagonists are found to be effective in preventing or reducing visual field loss associated with glaucoma. Especially preferred are certain 1-phenyl-2-piperidinoalkanol derivatives, such as eliprodil and ifenprodil.
    Type: Grant
    Filed: July 6, 1994
    Date of Patent: January 20, 1998
    Assignee: Synthelabo
    Inventors: Michael A. Kapin, Louis Desantis, Jr., Salomon Langer
  • Patent number: 5705510
    Abstract: The use of certain dopaminergic compounds for controlling elevations of intraocular pressure is disclosed. The compounds are ergoline derivatives. The most preferred compound is cabergoline. The compounds have been found to produce a significant reduction of intraocular pressure.
    Type: Grant
    Filed: October 25, 1995
    Date of Patent: January 6, 1998
    Assignee: Alcon Laboratories, Inc.
    Inventors: Louis DeSantis, Jr., Verney L. Sallee, Marsha A. McLaughlin, Manoj L. Maniar
  • Patent number: 5705530
    Abstract: Pharmaceutical compositions and a method are disclosed for treating glaucoma and/or ocular hypertension in the mammalian eye by administering to the mammalian eye the pharmaceutical composition of the invention which contains, as the active ingredient, one or more compounds having chloride channel blocking activity. Examples of chloride channel blockers utilized in the pharmaceutical composition and method of treatment are: ##STR1## wherein R is hydrogen or a pharmaceutically-acceptable cation, e.g. an alkali or alkaline earth metal, or a quaternary amine; or R represents a ester-forming moiety, e.g. a lower alkyl radical, having up to six carbon atoms, that may be derived from a lower alkanol.
    Type: Grant
    Filed: September 23, 1996
    Date of Patent: January 6, 1998
    Assignee: Allergan
    Inventors: Joseph S. Adorante, Elizabeth WoldeMussie, Guadalupe Ruiz
  • Patent number: 5700828
    Abstract: A method for treating or preventing anoxic or ischemic brain injury that includes administering melatonin to a person who is suffering from or has a high risk of suffering from an anoxic or ischemic insult or injury. The method may also include administering complementary agents.
    Type: Grant
    Filed: December 7, 1995
    Date of Patent: December 23, 1997
    Assignee: Life Resuscitation Technologies, Inc.
    Inventors: Michael G. Federowicz, Gregory M. Fahy, Lawrence E. Wood
  • Patent number: 5700835
    Abstract: Compositions containing 3-Oxa-D-prostaglandins and methods of their use in treating glaucoma or ocular hypertension are disclosed.
    Type: Grant
    Filed: December 22, 1995
    Date of Patent: December 23, 1997
    Assignee: Alcon Laboratories, Inc.
    Inventors: Thomas R. Dean, Mark Hellberg, Verney L. Sallee
  • Patent number: 5698598
    Abstract: The invention relates to the use of EP.sub.2 receptor agonists as potent ocular hypotensives, and are particularly suitable for the management of glaucoma. In particular said compounds are represented by the formulae: ##STR1## wherein the broken line attachment to the cyclopentane ring or the omega chain indicates the .alpha. configuration and the solid line attachment to the cyclopentane ring or the omega chain indicates the .beta. configuration, R is hydrogen or a saturated or unsaturated acyclic hydrocarbon group having from 1 to about 20 carbon atoms, or --(CH.sub.2).sub.m R.sub.1 wherein m is 0-10, and R.sub.1 is an aliphatic ring having from about 3 to about 7 carbon atoms, or an aryl or heteroaryl ring having from about 4 to about 10 carbon atoms and wherein the heteroatom is selected from the group consisting of N, O and S.
    Type: Grant
    Filed: August 4, 1995
    Date of Patent: December 16, 1997
    Assignee: Allergan
    Inventor: David F. Woodward
  • Patent number: 5696091
    Abstract: The intraocular use of combinations of lens epithelial cell growth stimulators (e.g., TGF-.beta.) and antimetabolites (e.g., mitomycin C) is described. The combination is applied to the capsular bag to prevent or retard the formation of secondary cataracts following cataract surgery. The lens epithelial cell stimulators activate DNA synthesis in dormant lens epithelial cells, and thereby make those cells susceptible to the anti-metabolites. This enables the antimetabolites to suppress the proliferation of lens epithelial cells to a much greater extent, relative to the proliferation observed when the metabolites alone are utilized. The increased suppression of the growth of lens epithelial cells results in a significant improvement in the ability to prevent or retard the formation of opacities on the lens capsule (i.e., secondary cataracts).
    Type: Grant
    Filed: February 20, 1996
    Date of Patent: December 9, 1997
    Assignee: Alcon Laboratories, Inc.
    Inventors: Billie M. York, Jon C. Nixon, Karen C. Sams
  • Patent number: 5693654
    Abstract: This invention relates to a new medical use for compounds having selective agonist activity at 5-HT.sub.1 -like receptors and to pharmaceutical compositions containing them. In particular it relates to a new medical use of 3-?2-(dimethylamino)ethyl!-N-methyl-1H-indole-5-methanesulphonamide and physiologically acceptable salts and solvates thereof for the treatment or prevention of elevated intraocular pressure, in particular glaucoma.
    Type: Grant
    Filed: February 6, 1995
    Date of Patent: December 2, 1997
    Assignee: Glaxo Group Limited
    Inventor: Phillip John Birch
  • Patent number: 5688770
    Abstract: The present invention relates to ophthalmo-logical pharmaceutical compositions comprising a renin inhibitor and to methods for using said composition in the treatment of glaucoma.
    Type: Grant
    Filed: April 7, 1994
    Date of Patent: November 18, 1997
    Assignee: Schering Corporation
    Inventor: Robert W. Watkins
  • Patent number: 5686407
    Abstract: Methods for controlling IOP with compositions of HGF Receptor Activators are disclosed.
    Type: Grant
    Filed: August 16, 1995
    Date of Patent: November 11, 1997
    Assignee: Alcon Laboratories, Inc.
    Inventors: Abbot F. Clark, Robert J. Wordinger
  • Patent number: 5683993
    Abstract: Compositions and methods for reducing the decomposition rate of polymeric bioadhesives and viscosity enhancers, such as poly(acrylic acids). The compositions include at least one strong, stable chelating agent, preferably an organophosphorous compound such as diethylene triamine penta(methylene phosphonic acid). These biocompatible compositions are especially useful in the ophthalmic field.
    Type: Grant
    Filed: June 22, 1995
    Date of Patent: November 4, 1997
    Assignee: CIBA Vision Corporation
    Inventor: Fu-Pao Tsao
  • Patent number: 5681825
    Abstract: Methods of facilitating surgical operations that involve the eye or eye area comprise introducing an opthalmologically acceptable composition containing hyaluronic acid into the site of the surgical operation. The hyaluronic acid comprises a chemically unmodified sterilized hyaluronic acid substance having a weight average molecular weight of from 4,500,000 to 12,000,000 daltons, a zero shear viscosity of from 1,000 to 80,000 Pas as measured on a 1.3-1.6% (wv) solution of hyaluronic acid substance in physiological phosphate buffer, and an absorbance at 257 nm of less than 3.5 when measured on a 1% solution of hyaluronic acid substance in sodium chloride buffer in a 10 mm cuvette. Preferred sterilized solutions of hyaluronic acid comprise hyaluronic acid which is chemically unmodified from the naturally occurring hyaluronic acid and has a weight average molecular weight of from 4,500,000 to 8,000,000 daltons, a zero shear viscosity of from 1,000 to 20,000 Pas and an absorbance at 257 nm of less than 3.5.
    Type: Grant
    Filed: March 21, 1995
    Date of Patent: October 28, 1997
    Inventors: Bengt Lindqvist, Daniel Ogbonnaya, Gillis Ponterius, Ove Wik
  • Patent number: 5677327
    Abstract: The present invention provides a method for identifying a compound having muscarinic agonist activity that will lower intraocular pressure without causing miosis which comprises measuring the activity of the compound at the m.sub.3 and m.sub.5 muscarinic receptors and determining from the activity measurement a compound having at least twice the agonist activity at the m.sub.5 receptor as compared to the m.sub.3 receptor. Preferably, the method of measuring said muscarinic agonist activity comprises eliciting phosphoinositide hydrolysis in CHO-K1 cells stably expressing the m.sub.3 and m.sub.5 muscarinic receptor subtypes. The present invention also provides a method of lowering the intraocular pressure in a mammal which comprises administering to said mammal a compound that has been determined to have at least twice the agonist activity at the m.sub.5 receptor as compared to the m.sub.3 receptor.
    Type: Grant
    Filed: June 22, 1995
    Date of Patent: October 14, 1997
    Assignee: Allergan
    Inventors: Daniel W. Gil, Elizabeth Woldemussie
  • Patent number: 5663205
    Abstract: A pharmaceutical composition for use in glaucoma treatment which contains as an active ingredient 5-[1-hydroxy-2-[2-(2-methoxyphenoxyl)ethylamino]ethyl]-2-methylbenzenesulf onamide of the formula: ##STR1## or its acid salt. This agent is free from side effects and stable and has an excellent intraocular pressure reducing activity at its low concentrations, thus being useful as a pharmaceutical composition for use in glaucoma treatment.
    Type: Grant
    Filed: November 15, 1994
    Date of Patent: September 2, 1997
    Assignee: Senju Pharmaceutical Co. Ltd.
    Inventors: Takahiro Ogawa, Takaaki Deguchi, Yoshifumi Ikejiri, Katsuhiro Inada
  • Patent number: 5658932
    Abstract: The present invention relates to therapeutically active azacyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful as stimulants of the cognitive function of the forebrain and hippocampus of mammals and especially in the treatment of Alzheimer's disease, severe painful conditions and glaucoma.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: August 19, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Per Sauerberg, Preben H. Olesen, Charles H. Mitch
  • Patent number: 5658950
    Abstract: The present invention provides a novel drug for treating glaucoma.The present invention relates to a therapeutic agent for glaucoma and an ocular hypotensive agent, which comprise an aminoalkoxybibenzyl represented by the formula (I): ##STR1## wherein R.sup.1 represents a hydrogen atom, a C.sub.1 -C.sub.5 alkoxy group, etc.; R.sup.2 represents a hydrogen atom, a halogen atom, etc.; R.sup.3 represents a hydrogen atom, a hydroxyl group, --O--CO--(CH.sub.2).sub.I --COOH (wherein I is an integer of 1 to 3), etc.; and R.sup.4 represents --NR.sup.5 R.sup.6 (wherein R.sup.5 and R.sup.6 independently represent a hydrogen atom or a C.sub.1 -C.sub.8 alkyl group), etc.or a salt thereof as an active ingredient.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: August 19, 1997
    Assignee: Mitsubishi Chemical Corporation
    Inventor: Tomiya Mano
  • Patent number: 5656635
    Abstract: The invention relates to the use of alcohol derivatives of F-type prostaglandins as ocular hypotensives. The PGF derivatives used in accordance with the invention are encompassed by the following structure formula I: ##STR1## wherein wavy line attachments indicate either the alpha (.alpha.) or beta (.beta.) configuration; hatched lined indicate .alpha. configuration, solid triangles are used to indicate .beta. configuration, dashed bonds represent a double bond, or a single bond; n is 0, or an integer of from 1 to 3; R is hydrogen or a --(CO)R.sub.4 group; R.sub.1, R.sub.2, and R.sub.3 independently are hydroxyl, or --O(CO)R.sub.5 groups, wherein R.sub.4 and R.sub.5 independently stand for saturated or unsaturated acyclic hydrocarbon having from 1 to 20 carbon atoms, or --(CH.sub.2).sub.m R.sub.6 where m is 0-10 and R.sub.6 is an aliphatic, aromatic or heteroaromatic ring, R.sub.7 and R.sub.8 independently are hydrogen or alkyl of 1 to 6 carbon atoms or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: June 8, 1993
    Date of Patent: August 12, 1997
    Assignee: Allergan
    Inventor: Ming Fai Chan
  • Patent number: 5652236
    Abstract: Pharmaceutical compositions and a method are disclosed for treating glaucoma and/or ocular hypertension in the mammalian eye by administering to the mammalian eye the pharmaceutical composition of the invention which contains as the active ingredient one or more compounds having guanylate cyclase inhibition activity. Examples of guanylate cyclase inhibitors utilized in the pharmaceutical composition and method of treatment are methylene blue, butylated hydroxyanisole and N-methylhydroxylamine.
    Type: Grant
    Filed: February 27, 1996
    Date of Patent: July 29, 1997
    Assignee: Allergan
    Inventor: Achim H. Krauss
  • Patent number: 5652272
    Abstract: The present invention provides an ophthalmic preparation for reducing intraocular pressure comprising 2-[3-dimethyl-amino-2-(2-carboxyethoxy)propionyloxy]-2'-methoxybibenzyl or a salt thereof, which preparation exhibits intraocular pressure reducing activity, without exerting effects on the central nervous system, and can advantageously be used as a prophylactic and therapeutic agent for ocular hypertension and glaucoma bringing about elevated intraocular pressure.
    Type: Grant
    Filed: March 15, 1995
    Date of Patent: July 29, 1997
    Assignee: Senju Pharmaceutical Co., Ltd.
    Inventors: Takahiro Ogawa, Takaaki Deguchi
  • Patent number: 5645827
    Abstract: Compositions comprising cationic polysaccharide polymers and anionic therapeutic agents which can have enhanced substantivity to mucosal surfaces are disclosed. These compositions are well suited, for example, for the delivery of anionic ophthalmic pharmaceuticals because they can provide clear solution in addition to substantivity.
    Type: Grant
    Filed: January 19, 1995
    Date of Patent: July 8, 1997
    Assignee: Union Carbide Chemicals & Plastics Technology Corporation
    Inventors: Lawrence Marlin, Ronald Kenichi Yamamoto
  • Patent number: 5646136
    Abstract: Methods for treating angiogenesis, tumors, and ocular hypertension with steroids are disclosed herein. The steroids have angiostatic activity with reduced glucocorticoid activity.
    Type: Grant
    Filed: January 4, 1994
    Date of Patent: July 8, 1997
    Assignee: Duke University
    Inventors: Vladimir Petrow, Alan D. Proia
  • Patent number: 5635172
    Abstract: Disclosed are nonstinging, sustained release ophthalmic formulations to control intraocular pressure in antiglaucoma therapy comprising a basic active, a cation exchange resin, and, inter alia, an acidic, mucomimetic polymer. Also disclosed are methods of treatment comprising administering such formulations topically to the eye when indicated for control and lowering of intraocular pressure.
    Type: Grant
    Filed: February 27, 1995
    Date of Patent: June 3, 1997
    Assignee: Alcon Laboratories, Inc.
    Inventors: Rajni Jani, Robert G. Harris
  • Patent number: 5631297
    Abstract: Anandamides useful for the treatment of intraocular hypertension, as well as ophthalmic compositions comprising the same and a cyclodextrin, and methods of use of these compounds to treat intraocular hypertension.
    Type: Grant
    Filed: July 11, 1994
    Date of Patent: May 20, 1997
    Inventors: David W. Pate, Tomi Jarvinen, Kristiina Jarvinen, Arto Urtti
  • Patent number: 5629345
    Abstract: ATP-sensitive K.sup.+ channel modulating compounds are incorporated into ophthalmically acceptable carriers for administration to the eye in order to affect intraocular pressure. Such formulations including compounds which inhibit the channel are particularly suitable for treating glaucoma and other disorders related to elevated intraocular pressure. Such formulation which potentiates the channel are particularly suitable for treating hypotonia and other depressed intraocular pressure conditions.
    Type: Grant
    Filed: July 23, 1993
    Date of Patent: May 13, 1997
    Assignee: Vide Pharmaceuticals
    Inventors: Nino Sorgente, Charles Bakhit
  • Patent number: 5627209
    Abstract: 9-Haloprostaglandins are useful in the treatment of glaucoma and ocular hypertension. Also disclosed are ophthalmic, pharmaceutical compositions comprising such prostaglandins.
    Type: Grant
    Filed: October 25, 1995
    Date of Patent: May 6, 1997
    Assignee: Alcon Laboratories, Inc.
    Inventors: Louis DeSantis, Jr., Verney L. Sallee
  • Patent number: 5627208
    Abstract: The invention relates to ophthalmological compositions for topical treatment of glaucoma or ocular hypertension comprising an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGD, PGE or PGF, in which the omega chain contains a ring structure, in an ophthalmologically compatible carrier. The invention further relates to the preparation of said compositions and their use for treatment of glaucoma or ocular hypertension.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: May 6, 1997
    Assignee: Pharmacia Aktiebolag
    Inventors: Johan W. Stjernschantz, Bahram Resul
  • Patent number: 5620970
    Abstract: The present invention is directed to topical ophthalmic formulations of carbonic anhydrase inhibitors and polyethoxylated derivatives of castor oil. Methods for using the formulations for treating and controlling glaucoma and ocular hypertension are also disclosed.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: April 15, 1997
    Assignee: Alcon Laboratories, Inc.
    Inventors: Wesley W. Han, Thomas R. Dean, Steven H. Gerson, Yusuf Ali, Rajni Jani
  • Patent number: 5618800
    Abstract: Drug delivery vehicles which reversibly increase in either loss modulus or storage modulus, or both, upon contact with the eye, skin, mucous membrane or body cavity are disclosed. The vehicles contain one or more nonionic substituted cellulose ethers and do not require a charged surfactant or a pH-sensitive polymer for such increase in loss modulus or storage modulus, or both, upon administration. In one embodiment, the vehicles gel upon instillation in the eye.
    Type: Grant
    Filed: August 23, 1995
    Date of Patent: April 8, 1997
    Assignee: Alcon Laboratories, Inc.
    Inventors: Bhagwati P. Kabra, John C. Lang
  • Patent number: 5612364
    Abstract: Compositions containing, and methods for controlling intraocular pressure with, substantially pure apraclonidine are disclosed.
    Type: Grant
    Filed: November 8, 1995
    Date of Patent: March 18, 1997
    Assignee: Alcon Laboratories, Inc.
    Inventors: Billie M. York, John M. Yanni, Mark T. DuPriest
  • Patent number: 5605922
    Abstract: Combinations of at least one clonidine derivative and at least one prostaglandin are used to treat glaucoma and ocular hypertension without some of the side effects typically associated with topical administration of prostaglandins.
    Type: Grant
    Filed: December 12, 1995
    Date of Patent: February 25, 1997
    Assignee: Alcon Laboratories, Inc.
    Inventors: Louis DeSantis, Jr., Verney L. Sallee
  • Patent number: 5603929
    Abstract: Disclosed are storage-stable preserved ophthalmic compositions containing acidic drugs in combination with polymeric quaternary ammonium compounds and boric acid.
    Type: Grant
    Filed: November 16, 1994
    Date of Patent: February 18, 1997
    Assignee: Alcon Laboratories, Inc.
    Inventors: Suketu D. Desai, Diane S. Nelms
  • Patent number: 5602143
    Abstract: Pharmaceutical compositions and a method are disclosed for treating glaucoma and/or ocular hypertension in the mammalian eye by administering to the mammalian eye the pharmaceutical composition of the invention which contains as the active ingredient one or more compounds having guanylate cyclase inhibition activity. Examples of guanylate cyclase inhibitors utilized in the pharmaceutical composition and method of treatment are: ##STR1## and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: December 8, 1994
    Date of Patent: February 11, 1997
    Assignee: Allergan
    Inventor: Achim H. Krauss
  • Patent number: 5599534
    Abstract: Reversibly gel-forming compositions for sustained delivery of bio-affecting substances are disclosed. The compositions exhibit significant changes in viscosity in response to changes in pH. The compositions contain relatively low concentrations of a stable combination of at least one pH-responsive gelling polymer and at least one other thermally nonresponsive polymer. The compositions are preferably formulated to include one or more therapeutic or diagnostic agents for administration as a liquid that will gel in situ or for topical application as a pre-formed gel.
    Type: Grant
    Filed: August 9, 1994
    Date of Patent: February 4, 1997
    Assignee: University of Nebraska
    Inventors: Kenneth J. Himmelstein, Cara L. Baustian
  • Patent number: 5599535
    Abstract: The invention concerns the recognition that certain non-steroidal anti-inflammatory agents produce cytoprotective effects on trabecular cells, and thus can be used to prevent injury to the cells and treat the loss of trabecular cells caused by oxidative or other forms of injury to the cells. Such treatment can ameliorate the severity, or prevent, glaucoma.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 4, 1997
    Assignee: Regents of the University of California
    Inventors: Jon R. Polansky, Ernest Bloom, Donald J. Fauss
  • Patent number: 5587175
    Abstract: Balanced pH, hyperosmotic, hypoosmotic, or isoosmotic gels are ideal vehicles for drug delivery. They are especially suited for topical body cavity or injection application of drugs or diagnostic agents; for drug or diagnostic agent delivery to the eye of a mammal; as protective corneal shields; or as ablatable corneal masks useful in laser reprofiling of the cornea. The compositions without the addition of a drug or diagnostic agent are useful as medical devices, for instance, in separating surgically or otherwise injured tissue as a means of preventing adhesions.
    Type: Grant
    Filed: December 28, 1993
    Date of Patent: December 24, 1996
    Assignee: MDV Technologies, Inc.
    Inventors: Tacey X. Viegas, Lorraine E. Reeve, Raymond L. Henry
  • Patent number: 5573758
    Abstract: Pharmaceutical compositions and a method are disclosed for treating glaucoma and/or ocular hypertension in the mammalian eye by administering to the mammalian eye the pharmaceutical composition of the invention which contains, as the active ingredient, one or more compounds having potassium channel blocking activity. Examples of potassium channel blockers utilized in the pharmaceutical composition and method of treatment are quinine, tremogenic indole alkaloids, such as Penitrem A and paspalicine, and insect toxins such as charybdotoxin and iberiotoxin.
    Type: Grant
    Filed: April 28, 1995
    Date of Patent: November 12, 1996
    Assignee: Allergan
    Inventors: Joseph S. Adorante, Elizabeth WoldeMussie, Guadalupe Ruiz
  • Patent number: 5565434
    Abstract: A method of reducing intraocular eye pressure by topically applying to an affected eye a small but therapeutically effective intraocular eye pressure reducing amount of a compound which is a 2-deoxyglucose or hexose or pentose derivative of ethacrynic acid.
    Type: Grant
    Filed: February 23, 1996
    Date of Patent: October 15, 1996
    Assignee: University of Iowa Research Foundation
    Inventors: Charles F. Barfknecht, Ronald D. Schoenwald